medigraphic.com
ISSN 1561-302X (Print)

2014, Number 3

<< Back Next >>

Rev cubana med 2014; 53 (3)

Effect of treatment with oral red propolis extract on nonalcoholic teatohepatitis

Fernández VD, Velbes MPE, Nasiff HA, Domínguez ÁC, Soto MJ, Giral RT

Language: Spanish
References: 17
Page: 282-290
PDF size: 167.35 Kb.


ABSTRACT

Introduction: nonalcoholic steatohepatitis is a common condition which may lead to cirrhosis. The existing drug therapy options are not very effective. It is a well known fact that propolis has an antioxidant and antiinflammatory effect. Reports on the benefits of propolis may be found in the literature.
Objective: identify histological hepatic changes in patients with steatohepatitis treated with 5% hydroalcoholic oral extract of Cuban red propolis for a year.
Methods: a double-blind randomized controlled clinical trial was conducted with 40 patients of both sexes aged 20-65 with 6-8 Kleiner index, who were divided in 2 groups: propolis and placebo. Statistical analysis was based on chi-square and nonparametric tests.
Results: total Kleiner decreased from 6 ± 0.65 to 3.15 ± 071 in the propolis group and from 6±0.65 to 6.1±0.97 in the placebo group. In the propolis group there was also a decrease in steatosis, inflammation, ballooning and fibrosis. Changes in liver enzymes and plasmatic lipoproteins were favorable.
Conclusions: red propolis may be a therapeutic alternative to stop the progress of esteatohepatitis.


REFERENCES

  1. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2006;40(3).S34-8.

  2. Farrell GC , Larter CZ. Nonalcoholic fatty liver disease. from steatosis to cirrhosis. Hepatol Res. 2006;34(2):92-8.

  3. Feldstein AE, Charatcharoenwitthaya PST, Benson JT, Enders FB, Angulo P. The Natural History of Nonalcoholic Fatty Liver Disease in Children. A Follow-Up Study For Up To 20 Years. Hepatology. 2008;48(3):64A.

  4. Herrera GA, Nasiff HA, Arus SE, Cand HC, León N. Hígado graso. Enfoque diagnóstico y terapéutico. Rev Cubana Med. 2007;46(1):11-4.

  5. Clark M. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(3):S5-10.

  6. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis. implications for treatment. Am J Gastroenterol. 2008;103:1036-42.

  7. Rafiq N, Bai C, Fand Y, Srishord MK, McCullough AJ, Younossi ZM. Over twenty five years of follow up for a Non-Alcoholic Fatty Liver Disease Cohort. Gastroenterology. 2008;134:A754.

  8. Bracho JC, Tabío C, Valdés G, Gil J, Dominguez A, Mendoza L. Control de la calidad de propóleos (Características cualitativas y cuantitativas). Apitec. nov. 1996;4(3):15-6.

  9. Cuesta-Rubio O, Piccinelli AL, Fernández M, Hernández I, Rosado A, Rastrelli L. Chemical characterization of Cuban propolis by HPLC-PDA, HPLC-MS, and NMR. the brown, red, and yellow Cuban varieties of propolis Instituto de Farmacia y Alimentos. Journal of Agricultural and Food Chemistry. 2007;55(18):7502-9.

  10. Campo Fernández M, Cuesta-Rubio O, Rosado Pérez A, Montes de Oca Porto R, Márquez Hernández I, Piccinelli AL, et al. GC-MS determination of isoflavonoids in seven red Cuban propolis samples. J Agr Food Chem. 2008;56(23):9927-32.

  11. Mani F, Damasceno HCR, Novelli ELB, Sforcin JM. Biochemical determinations of propolis-treated rats. effects of different concentrations, extracts and intake period. Biosáude. 2008;10:3-16.

  12. Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;32(8):976-84.

  13. García Rochet C, Balbuena E, Domínguez E. Esteatosis hepática en diabéticos, comportamiento en el Hospital Saturnino Lora durante un año [tesis]. Santiago de Cuba: Instituto Superior de Ciencias Médicas Santiago de Cuba; 2005.

  14. Hisamitsu M, Tatsuki I, Kazuhiko N, Hiroshi Y, Ryuji F, Kazuo O, et al. Clinicopathological study of nonalcoholic fatty liver disease in Japan. the risk factors for fibrosis. Clinical Studies. 2007;21(3):1478-3223.

  15. Adams LA, Paul A. Role of liver biopsy and serum markers of liver fibrosis in non-alcoholic fatty liver disease. Clin Liver Dis. 2007;11:25-35.

  16. Guatemala Martínez ML, Velbes Marquetti Pedro E, Gra Oramas B. Factores predictivos de fibrosis hepática en pacientes con hígado graso no alcohólico [tesis]. La Habana: Hospital Clinicoquirúrgico "Hermanos Ameijeiras"; 2005.

  17. Sreenivasa BC, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2006;21:191-8.




2020     |     www.medigraphic.com